porna

Market Research Reports and Industry Reports

Treating Refractory Hematological Malignancies Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Emerging Therapeutics

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
The report provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing this therapy area Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.

Detailed financial and competitive analysis of the companies leading in the race to launch new therapies for this indication Ambit Biosciences, Onconova Therapeutics, SymBio Pharma, and Celgene are available as a separate or with the full report. Key M&A activities that have taken place in this area in the last 5 years and a list of products in early /late stages of development available for in-licensing are highlighted in the report. This report is built using primary and secondary research data and in-house proprietary database.
Table 1
Refractory MDS/ RR AML: Emerging Therapeutics
REVISED INTERNATIONAL PROGNOSIS SCORING SYSTEM (IPSS-R)
Table 2
Refractory MDS/ RR AML: Emerging Therapeutics
COMPETITIVE LANDSCAPE: RR/ HIGH-RISK MDS AND RR AML
Table 3
Refractory MDS/ RR AML: Emerging Therapeutics
COMPETITIVE LANDSCAPE: UNTREATED/ NEWLY DIAGNOSED MDS AND AML
Table 4
Refractory MDS/ RR AML: Emerging Therapeutics
LAUNCH TIMELINE AND MARKET POTENTIAL
Table 5
Refractory MDS/ RR AML: Emerging Therapeutics
SELECT M&A AND LICENSING DEALS IN LAST 5 YEARS 2007 to 2012
Table 6
Refractory MDS/ RR AML: Emerging Therapeutics
SELECT M&A AND LICENSING DEALS OPPORTUNITIES
Table 7
Ambit Biosciences
NPV VALUATION- Base Case
Table 8
Ambit Biosciences
NPV VALUATION EARLY APPROVAL

Table 9
Ambit Biosciences
COMPETITIVE LANDSCAPE SELECT LATE AND MID STAGE DRUG TARGETING AML
Table 10
Ambit Biosciences
SELECT JAK 2/1 INHIBITORS: MID- TO LATESTAGE PIPELINE
Table 11
Onconova Therapeutics
NPV VALUATION Table 12
Onconova Therapeutics
COMPETITION IN RR MDS/ AML SELECT LATE- TO MID- STAGE COMPOUNDS

List Of Tables

Figure 1
Ambit Biosciences
MONOTHERAPY RESPONSE RATES (CRc) IN AML
Figure 2
Ambit Biosciences
QUIZARITINIB PhIIb COMPARABLE EFFICACY WITH LOWER DOSES
Figure 3
Ambit Biosciences
QTC PROLONGATION AT VARIOUS DOSES OF QUIZARTINIB
Figure 4
Ambit Biosciences
LONG TERM SURVIVORS IN PHASE 2 - TREATED WITH QUIZARTINIB
Figure 5
Ambit Biosciences
QUIZARTINIB MARKET OPPORTUNITY IN US IN AML
Figure 6
Ambit Biosciences
OVERALL SURVIVAL FOR AML PTS LESS THAN 60 YEAR OLD WITH FLT3 ITD MUTATION
Figure 7
Ambit Biosciences
PROPOSED PHIII TRIAL OF QUIZARTINIB
Figure 8
Onconova Therapeutics
PHIII TRIAL DESIGN ONTIME
Figure 9
Onconova Therapeutics
ITT ANALYSIS: SURVIVAL DATA FOR REFRACTORY MDS PTS
Figure 10
Onconova Therapeutics
BEST BONE MARROW (BM) RESPONSES AFTER RIG. IV
Figure 11
Onconova Therapeutics
PHII TRIAL DESIGN ONTARGET
Figure 12
Onconova Therapeutics
PHIII TRIAL DESIGN ONTRAC



List Of Figures

Table 1
Refractory MDS/ RR AML: Emerging Therapeutics
REVISED INTERNATIONAL PROGNOSIS SCORING SYSTEM (IPSS-R)
Table 2
Refractory MDS/ RR AML: Emerging Therapeutics
COMPETITIVE LANDSCAPE: RR/ HIGH-RISK MDS AND RR AML
Table 3
Refractory MDS/ RR AML: Emerging Therapeutics
COMPETITIVE LANDSCAPE: UNTREATED/ NEWLY DIAGNOSED MDS AND AML
Table 4
Refractory MDS/ RR AML: Emerging Therapeutics
LAUNCH TIMELINE AND MARKET POTENTIAL
Table 5
Refractory MDS/ RR AML: Emerging Therapeutics
SELECT M&A AND LICENSING DEALS IN LAST 5 YEARS 2007 to 2012
Table 6
Refractory MDS/ RR AML: Emerging Therapeutics
SELECT M&A AND LICENSING DEALS OPPORTUNITIES
Table 7
Ambit Biosciences
NPV VALUATION- Base Case
Table 8
Ambit Biosciences
NPV VALUATION EARLY APPROVAL

Table 9
Ambit Biosciences
COMPETITIVE LANDSCAPE SELECT LATE AND MID STAGE DRUG TARGETING AML
Table 10
Ambit Biosciences
SELECT JAK 2/1 INHIBITORS: MID- TO LATESTAGE PIPELINE
Table 11
Onconova Therapeutics
NPV VALUATION Table 12
Onconova Therapeutics
COMPETITION IN RR MDS/ AML SELECT LATE- TO MID- STAGE COMPOUNDS

Gibson Energy Custom Treating and Terminals Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

Gibson Energy Custom Treating and Terminals Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market

USD 200View Report

Global Hydro Treating Catalysts Sales Market Report 2016

Notes:Sales, means the sales volume of Hydro Treating CatalystsRevenue, means the sales value of Hydro Treating CatalystsThis report studies sales (consumption) of Hydro Treating Catalysts in Global market, especially in

USD 4000View Report

United States Hydro Treating Catalysts Market Report 2016

Notes:Sales, means the sales volume of Hydro Treating CatalystsRevenue, means the sales value of Hydro Treating CatalystsThis report studies sales (consumption) of Hydro Treating Catalysts in United States market, focuses

USD 3800View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 2500
  • Site Licence    $ 5000
  • Enterprisewide Licence    $ 7500
$ 2500

Reports Details

Published Date : Aug 2013
No. of Pages :37
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment